Updated NETs Clinical Trials

Studies found on ClinicalTrials.gov by a search of: neuroendocrine NOT Melanoma NOT PMS | Recruiting, Not yet recruiting, Available Studies | Phase 2, 3, 4 | Last update posted in the last 30 days
  1. Condition:   Neuroendocrine Carcinoma
    Interventions:   Drug: CPT-11;   Drug: Calcio levofolinate;   Drug: 5-Fluorouracil;   Drug: Capecitabine;   Drug: Temozolomide
    Sponsor:   Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
    Recruiting
  2. Conditions:   Advanced Digestive System Neuroendocrine Neoplasm;   Digestive System Neuroendocrine Tumor;   Foregut Carcinoid Tumor;   Hindgut Carcinoid Tumor;   Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm;   Metastatic Digestive System Neuroendocrine Neoplasm;   Midgut Carcinoid Tumor;   Pancreatic Neuroendocrine Tumor;   Refractory Digestive System Neuroendocrine Neoplasm
    Intervention:   Drug: Abemaciclib
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  3. Conditions:   Locally Advanced Digestive System Neuroendocrine Carcinoma;   Locally Advanced Pancreatic Neuroendocrine Carcinoma;   Metastatic Digestive System Neuroendocrine Carcinoma;   Metastatic Pancreatic Neuroendocrine Carcinoma;   Refractory Digestive System Neuroendocrine Carcinoma;   Refractory Pancreatic Neuroendocrine Carcinoma;   Unresectable Digestive System Neuroendocrine Carcinoma;   Unresectable Pancreatic Neuroendocrine Carcinoma
    Interventions:   Drug: Fluorouracil;   Drug: Leucovorin;   Drug: Liposomal Irinotecan;   Procedure: Quality-of-Life Assessment
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Ipsen
    Recruiting
  4. Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Digestive System Neuroendocrine Neoplasm;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Neuroendocrine Tumor;   Serotonin-Producing Pancreatic Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  5. Conditions:   Grade I Neuroendocrine Carcinoma;   Grade II Neuroendocrine Carcinoma;   Grade III Neuroendocrine Carcinoma;   Metastatic Neuroendocrine Carcinoma;   Neuroendocrine Carcinoma;   Recurrent Small Cell Lung Carcinoma;   Refractory Small Cell Lung Carcinoma;   Lung Cancer Stage IV;   Large Cell Neuroendocrine Carcinoma;   Neuroendocrine Tumors;   Small Cell Lung Cancer Metastatic;   Small-cell Lung Cancer
    Interventions:   Biological: Nivolumab;   Drug: Temozolomide
    Sponsors:   Dwight Owen;   National Cancer Institute (NCI)
    Recruiting
  6. Conditions:   Small Cell Carcinoma;   Carcinoma, Non-Small-Cell Lung;   Neuroendocrine Tumors;   Ovarian Epithelial Cancer
    Interventions:   Drug: RRx-001;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Carboplatin;   Drug: Irinotecan;   Drug: Vinorelbine;   Drug: Doxil;   Drug: Gemcitabine;   Drug: Taxane;   Drug: Paclitaxel;   Drug: Nab-Paclitaxel;   Drug: Pemetrexed
    Sponsor:   EpicentRx, Inc.
    Recruiting
  7. Condition:   Neuroendocrine Tumors
    Interventions:   Radiation: 18F-MFBG (meta-fluoro benzylguanidine);   Device: Positron emission tomography (PET) imaging;   Other: Blood draws
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting
  8. Conditions:   Gastroenteropancreatico Tumors;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Olaparib;   Diagnostic Test: Ga dotatate scanning;   Diagnostic Test: FDG-PET scanning
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting
  9. Conditions:   Head Neck Tumors;   Neuroendocrine Tumors;   Soft Tissue Sarcoma;   Rare Cancer;   Vaccination
    Interventions:   Biological: Autologous DC vaccine;   Drug: Interleukin-2
    Sponsor:   Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
    Not yet recruiting
  10. Condition:   Neuroendocrine Tumors
    Intervention:   Drug: Satoreotide tetraxetan
    Sponsor:   Ipsen
    Recruiting
  11. Condition:   Tumors
    Intervention:   Drug: surufatinib
    Sponsor:   Hutchison Medipharma Limited
    Recruiting
  12. Conditions:   Metastatic Prostate Adenocarcinoma;   Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation;   Recurrent Prostate Carcinoma;   Stage IVB Prostate Cancer AJCC v8
    Interventions:   Drug: Abiraterone Acetate;   Drug: Apalutamide;   Drug: Leuprolide Acetate;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Body Radiation Therapy
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting
  13. Conditions:   KRAS Gene Mutation;   Metastatic Colorectal Carcinoma;   NRAS Gene Mutation;   Stage III Colorectal Cancer AJCC v8;   Stage IIIA Colorectal Neuroendocrine Tumor AJCC v8;   Stage IIIB Colorectal Cancer AJCC v8;   Stage IIIC Colorectal Cancer AJCC v8;   Stage IV Colorectal Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVB Colorectal Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8;   Unresectable Carcinoma
    Interventions:   Drug: Binimetinib;   Drug: Palbociclib;   Drug: Trifluridine and Tipiracil Hydrochloride
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Recruiting
  14. Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  15. Conditions:   Lung Non-Small Cell Squamous Carcinoma;   Minimally Invasive Lung Adenocarcinoma;   Neuroendocrine Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Large Cell Carcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Stage I Lung Cancer AJCC v8;   Stage IA1 Lung Cancer AJCC v8;   Stage IA2 Lung Cancer AJCC v8;   Stage IA3 Lung Cancer AJCC v8;   Stage IB Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8
    Interventions:   Biological: Nivolumab;   Radiation: Stereotactic Body Radiation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  16. Conditions:   Sarcoma;   Ovarian Neoplasm;   Central Nervous System Neoplasm;   Thyroid Neoplasm;   Carcinoma, Neuroendocrine;   Neoplasms, Germ Cell and Embryonal;   NK/T-cell Lymphoma
    Intervention:   Drug: Pembrolizumab
    Sponsors:   UNICANCER;   National Cancer Institute, France;   Ligue contre le cancer, France;   Merck Sharp & Dohme Corp.
    Recruiting
  17. Conditions:   RET-altered Non Small Cell Lung Cancer;   Medullary Thyroid Cancer;   RET-altered Papillary Thyroid Cancer;   RET-altered Colon Cancer;   RET-altered Solid Tumors;   Lung Neoplasm;   Carcinoma, Non-Small-Cell Lung;   Thyroid Diseases;   Thyroid Neoplasm;   Thyroid Cancer, Papillary;   Carcinoma, Neuroendocrine;   Respiratory Tract Neoplasms;   Thoracic Neoplasms;   Neoplasms by Site;   Neoplasms;   Lung Diseases;   Respiratory Tract Disease;   Carcinoma, Bronchogenic;   Bronchial Neoplasms;   Endocrine System Diseases;   Endocrine Gland Neoplasm;   Head and Neck Neoplasms;   Adenocarcinoma, Papillary;   Adenocarcinoma;   Carcinoma;   Neoplasms, Glandular and Epithelial;   Neoplasms by Histologic Type;   Neuroendocrine Tumors;   Neuroectodermal Tumors;   Neoplasms, Germ Cell and Embryonal;   Neoplasms, Nerve Tissue;   Colonic Neoplasms;   Colorectal Neoplasms;   Intestinal Neoplasms;   Gastrointestinal Neoplasms;   Digestive System Neoplasm;   Digestive System Disease;   Gastrointestinal Disease;   Colonic Diseases;   Intestinal Disease
    Intervention:   Drug: pralsetinib (BLU-667)
    Sponsor:   Blueprint Medicines Corporation
    Recruiting
  18. Conditions:   Locally Advanced Solid Tumors;   Metastatic Solid Tumors
    Intervention:   Drug: Oral repotrectinib (TPX-0005)
    Sponsor:   Turning Point Therapeutics, Inc.
    Recruiting
  19. Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  20. Condition:   Breast Cancer
    Interventions:   Drug: alpelisib;   Drug: fulvestrant;   Drug: letrozole;   Drug: Goserelin;   Drug: Leuprolide
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  21. Condition:   Cushing's Syndrome
    Intervention:   Drug: osilodrostat
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  22. Conditions:   Pathologic Stage I Merkel Cell Carcinoma AJCC v8;   Pathologic Stage II Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
    Interventions:   Other: Best Practice;   Biological: Pembrolizumab;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  23. Condition:   Metastatic Merkel Cell Carcinoma
    Intervention:   Drug: INCMGA00012
    Sponsor:   Incyte Corporation
    Recruiting
  24. Conditions:   Stage III Merkel Cell Carcinoma AJCC v7;   Stage IIIA Merkel Cell Carcinoma AJCC v7;   Stage IIIB Merkel Cell Carcinoma AJCC v7;   Stage IV Merkel Cell Carcinoma AJCC v7
    Interventions:   Biological: Pembrolizumab;   Radiation: Stereotactic Body Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  25. Conditions:   Acquired Immunodeficiency Syndrome;   BK Virus Infection;   Human Immunodeficiency Virus;   JC Virus Infection;   Malignant Neoplasm;   Merkel Cell Carcinoma;   Merkel Cell Polyomavirus Infection;   Viral Encephalitis
    Interventions:   Biological: Allogeneic BK-specific Cytotoxic T-lymphocytes;   Other: Laboratory Biomarker Analysis
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  26. Conditions:   Schwannomatosis;   Pain
    Interventions:   Drug: Tanezumab;   Drug: Placebo
    Sponsors:   Massachusetts General Hospital;   Pfizer
    Not yet recruiting
  27. Condition:   Vestibular Vertigo
    Interventions:   Drug: Intranasal Drug;   Drug: Oral Tablet;   Other: Intranasal Placebo
    Sponsor:   Auris Medical AG
    Recruiting
  28. Conditions:   Paraganglioma;   Gastrointestinal Stromal Tumors;   Carcinoma, Renal Cell;   Renal Neoplasms;   Pheochromocytoma
    Intervention:   Drug: SGI-110 (guadecitabine)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  29. Conditions:   Castration Levels of Testosterone;   Castration-Resistant Prostate Carcinoma;   Metastatic Prostate Carcinoma in the Soft Tissue;   Prostate Carcinoma Metastatic in the Bone;   PSA Level Greater Than or Equal to Two;   PSA Progression;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8
    Interventions:   Drug: Decitabine;   Drug: Enzalutamide
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Not yet recruiting